Eradication efficacy of empiric bismuth quadruple therapy containing amoxicillin in the first-line treatment of Helicobacter pylori in Ningxia, China
Abstract
BACKGROUND: This study aimed to evaluate the eradication rate and safety of bismuth quadruple therapy containing amoxicillin as a first-line empiric treatment in patients with high resistance to Helicobacter pylori (H. pylori) in China. METHODS: This retrospective study included 874 patients with H. pylori infection who attended the outpatient clinic of the Department of Gastroenterology of the People’s Hospital of Ningxia Hui Autonomous Region from June 2021 to October 2022 and met the criteria for exclusion, including the Esomeprazole-Bismuth-Amoxicillin-Clarithromycin (EBAC) group, the Esomeprazole-Bismuth-Amoxicillin-Levofloxacin (EBAL) group, the Esomeprazole-Bismuth-Amoxicillin-Furazolidone (EBAF) group, the Esomeprazole-Bismuth-Amoxicillin-Tetracycline (EBAT) group, and the duration of treatment was 14 days. Eradication of H. pylori was determined using a repeat 14-carbon urease breath test (14 C-UBT) at weeks 4–6 after the end of treatment. RESULTS: In the intention-to-treat analysis (ITT), the eradication rates of H. pylori in the EBAC, EBAL, EBAF, and EBAT groups were 73.2% (198.5/271), 69.0% ( 184.9/268), 71.8% (109.2/152), and 71.5% (130.2/183), respectively; and in the per-protocol (PP) analysis, the PP analysis eradication rates were 83.2% (203.9/245), 81.2% (193.3/238), 90.0% (124.3/138), and 82.5% (136.1/165), and the differences in the eradication rates of the four groups for ITT and PP analysis were not statistically significant (ITT: P = 0.845; PP: P =…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 874 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.